Advances in Vaccine Technology

Chapter

Abstract

Human papillomaviruses (HPVs) are the causative agent for recurrent respiratory papillomatosis, cancer of the cervix, and squamous cell carcinoma of the head and neck. Vaccines are available to prevent infection with several of the HPV types that are responsible for causing these serious diseases. This chapter discusses the development, successes, and limitations of these prophylactic L1-based vaccines. Potential for L2-based vaccines to provide broad coverage to prevent infection with many HPV types is also discussed. Finally, research into treatment of established HPV infection and resultant disease using therapeutic vaccines is outlined.

Keywords

Human papillomavirus Vaccine Gardasil Cervarix Recurrent respiratory papillomatosis 

References

  1. (CDC) CfDCaP. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep. 2013;62(29):591–5.Google Scholar
  2. Angioli R, Lopez S, Aloisi A, Terranova C, DeCicco C, et al. Ten years of HPV vaccines: state of art and controversies. Crit Reviews Oncol Hematol. 2016;102:65–72.CrossRefGoogle Scholar
  3. Bayas JM, Costas L, Munoz A. Gynecol Oncol. Cervical cancer vaccination indications, efficacy, and side effects. 2008;110(3 Suppl 2):S11–4.Google Scholar
  4. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27:5450–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Brotherton JML, Ogilvie GS. Current status of human papillomavirus vaccination. Curr Opin Oncol. 2015;27:399–404.CrossRefPubMedGoogle Scholar
  6. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105–12.CrossRefPubMedGoogle Scholar
  7. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144:449–68.CrossRefPubMedGoogle Scholar
  8. Centers for Disease Control and Prevention. Human papillomavirus-associated cancers—United States, 2004–2008. Morbidity Mortality Weekly Rep. 2012;61(15):258–61.Google Scholar
  9. Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines. 2014;13(11):1279–90.CrossRefPubMedGoogle Scholar
  10. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007;40(2):108–15.CrossRefPubMedGoogle Scholar
  11. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe. 2010;8:260–70.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis; a review. Laryngoscope. 2008;118:1236–47.CrossRefPubMedGoogle Scholar
  13. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802.CrossRefPubMedGoogle Scholar
  14. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006;194:1044–57.CrossRefPubMedGoogle Scholar
  15. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85:499–502.CrossRefPubMedGoogle Scholar
  16. Farrow AL, Rachakonda G, Gu L, Krendelchtchikova V, Nde PN, Pratap S, et al. Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2014;8(8):e3089.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3):e657–65.CrossRefPubMedGoogle Scholar
  18. Fraillery D, Baud D, Pang SY. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol. 2007;14:1285–95.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Garland SM. The Australian experience with the human papillomavirus vaccine. Clinical Therapeut. 2014;36:17–23.CrossRefGoogle Scholar
  20. Gérard CM, Baudson N, Kraemer K, Bruck C, Garçon N, Paterson Y, Pan ZK, Pardoll D. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine. 2001;19(17–19):2583–9.CrossRefPubMedGoogle Scholar
  21. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10 Suppl):3036–46.CrossRefPubMedGoogle Scholar
  22. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomark Prev. 2008a Aug;17(8):2036–43.CrossRefGoogle Scholar
  23. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis. 2008b;198:827–35.CrossRefPubMedGoogle Scholar
  24. Giuliano AR, Palefksy JM, Goldstone S, et al. Efficacy of Quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401–11.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Guo T, Eisele DW, Fahkry C. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer. 2016;122(15):2313–23.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Handler MZ, Handler NS, Majewski S, Schwartz RA. Human papillomavirus vaccine tirals and tribulations: clinical perspectives. J Am Acad Dermatol. 2015;73:743–56.CrossRefPubMedGoogle Scholar
  27. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health and nutrition examination survey, 2003–2006. J Infect Dis. 2011;204(4):566–73.CrossRefPubMedGoogle Scholar
  28. Harper DM, Vierthaler SL, Santee JA. Review of Gardasil. J Vaccines Vaccin. 2010;1(107):1000107.PubMedPubMedCentralGoogle Scholar
  29. Harro CD, Pang YY, Roden RB, Hildesheim A. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93:284–92.CrossRefPubMedGoogle Scholar
  30. Hermann JS, Weckx LY, Nurnberger JM, Dos Santos Junior GF, et al. Effectiveness of the human papillomavirus (types 6,11,16,18) vaccine in the treatment of children with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2016;83:94–8.CrossRefPubMedGoogle Scholar
  31. Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16:e206–16.CrossRefPubMedGoogle Scholar
  32. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743–53.CrossRefPubMedGoogle Scholar
  33. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst. 2009;101(11):782–92.CrossRefPubMedPubMedCentralGoogle Scholar
  34. Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, Chivukula SV, et al. Optimization of multimeric human papillomavirus L2 vaccines. PLoS One. 2013;8(1):e55538.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Jeyakumar A, Mitchell M. HPV vaccination and recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 2011;144:133.CrossRefPubMedGoogle Scholar
  36. Karanam B, Jagu S, Huh WK, Roden RB. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009a;87(4):287–99.CrossRefPubMedPubMedCentralGoogle Scholar
  37. Karanam B, Jagu S, Huh WK, Roden RBS. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009b;87:287–99.CrossRefPubMedPubMedCentralGoogle Scholar
  38. Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, et al. Vaccination against HPV-16 Oncoproteins for vulvar intraepithelial Neoplasia. N Engl J Med. 2009;361:1838–47.CrossRefPubMedGoogle Scholar
  39. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645–51.CrossRefPubMedGoogle Scholar
  40. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444–51.CrossRefPubMedPubMedCentralGoogle Scholar
  41. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prevent Res (Philadelphia). 2012;5(1):18–23.CrossRefGoogle Scholar
  42. Makiyama K, Hirai R, Matsuzaki H. Gardasil vaccination for recurrent laryngeal papillomatosis in adult men; changes in HPV antibody titer. J Voice. 2016;Pii:S0892–1997. doi: 10.1016/j.jvoice.2016.01.008.Google Scholar
  43. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, et al. Quadrivalent human papilloma vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;23(56(RR-2):1–24.Google Scholar
  44. Markowitz LE, Tsu V, Deeks SL, Cubie H, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine. 2012;30S:F139–48.CrossRefGoogle Scholar
  45. Marlow LA, Forster AS, Wardle J, Waller J. Mothers' and adolescents' beliefs about risk compensation following HPV vaccination. J Adolesc Health. 2009;44(5):446–51.CrossRefPubMedGoogle Scholar
  46. Nygård M, Krüger Kjaer S, Dillner J, et al. Long-term effectiveness and immunogenicity of Gardasil™ in the Nordic countries. In: Poster presented at Eurogin 2013: HPV at a Crossroads – 30 Years of Research and Practice; 3–6 Nov 2013. Florence, Italy.Google Scholar
  47. Palefsky JM, Giuliano AR, Goldstone S. HPV vaccine against anal HPV infection and anal intraepithelial Neoplasia. N Engl J Med. 2011;365(17):1576–85.CrossRefPubMedGoogle Scholar
  48. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology. 2005;337(2):365–72.CrossRefPubMedGoogle Scholar
  49. Peng S, Tomson TT, Trimble C, He L, Hung CF, Wu TC. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther. 2006;13:257–65.CrossRefPubMedPubMedCentralGoogle Scholar
  50. Peng S, Best SR, Hung CF, et al. Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. Laryngoscope. 2010;120(3):504–10.CrossRefPubMedPubMedCentralGoogle Scholar
  51. Peng S, Song L, Knoff J, Wang JW, et al. Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell Biosci. 2014;4(1):11.CrossRefPubMedPubMedCentralGoogle Scholar
  52. Peng S, Mattox A, Best SR, et al. Identification of the murine H-2D(B) and human HLA-A*0201 MHC class i-restricted HPV6 E7-specific cytotoxic t lymphocyte epitopes. Cancer Immunol Immunother. 2016;65(3):261–71. Epub 2016 Jan 13CrossRefPubMedGoogle Scholar
  53. Ports KA, Barnack-Tavlaris JL, Mosavel M, et al. Young Women’s sexual and reproductive health post HPV vaccination Womens Reprod health. Womens Reprod Health. 2014;1(1):43–55.CrossRefPubMedCentralGoogle Scholar
  54. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007;13(7):857–61.CrossRefPubMedGoogle Scholar
  55. Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology. 2000;270(2):254–7.CrossRefPubMedGoogle Scholar
  56. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374–86.CrossRefPubMedPubMedCentralGoogle Scholar
  57. Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol. 2013;133(12):2706–13.CrossRefPubMedPubMedCentralGoogle Scholar
  58. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol. 1996;7:373–82.CrossRefPubMedGoogle Scholar
  59. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26(Suppl 10):K53–61.CrossRefPubMedPubMedCentralGoogle Scholar
  60. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–38.CrossRefPubMedPubMedCentralGoogle Scholar
  61. Shah KV. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent vaccine to prevent juvenile-onset laryngeal papilloma. J Infect Dis. 2014;209:1307–9.CrossRefPubMedGoogle Scholar
  62. Sharma A, Krause A, Xu Y, Sung B, Wu W, Worgall S. Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas Aeruginosa. PLoS One. 2013;8(2):e56996.CrossRefPubMedPubMedCentralGoogle Scholar
  63. van der Sluis TC, Sluijter M, van Duikeren S, West BL, Melief CJ, Arens R, et al. Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression. Cancer Immunol Res. 2015;3(9):1042–51.CrossRefPubMedGoogle Scholar
  64. State Vaccination Requirements. 29 Jan 2016. Retrieved July 19, 2016, from http://www.cdc.gov/vaccines/imz-managers/laws/state-reqs.html.
  65. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92(25):11553–7.CrossRefPubMedPubMedCentralGoogle Scholar
  66. TjonPianGi REA, San Giorgi MRM, Pawlita M, Michel A, et al. Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. Arch Otorhinolaryngol. 2016;273:3231–6. doi: 10.1007/s00405-016-4085-3.CrossRefGoogle Scholar
  67. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–88.CrossRefPubMedPubMedCentralGoogle Scholar
  68. Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One. 2012;7(11):e49751.CrossRefPubMedPubMedCentralGoogle Scholar
  69. Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines. 2013;12(2):129–41.CrossRefPubMedGoogle Scholar
  70. Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Virol J. 2015;12:140.CrossRefPubMedPubMedCentralGoogle Scholar
  71. Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, et al. Oral administration of HPV-16 L2 displayed on lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine. 2012;30(22):3286–94.CrossRefPubMedGoogle Scholar
  72. Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (Gardasil) as adjuvant therapy for treatment of recurrent respiratory papilloma. J Voice 2015; 229:223–229.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Julie Ahn
    • 1
  • Simon R. A. Best
    • 1
  • David E. Tunkel
    • 1
  1. 1.Department of Otolaryngology—Head and Neck SurgeryJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations